Herriot Tabuteau - 26 Feb 2026 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: AXSM
Reported as of: 26 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Feb 2026, 19:10:09 UTC
Prior SEC filing: 02 Feb 2026
Next SEC filing: 23 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Herriot Tabuteau, M.D.

Key filing fact

Herriot Tabuteau filed Form 4 for Axsome Therapeutics, Inc. (AXSM) on 27 Feb 2026.

Key facts

This page summarizes Herriot Tabuteau's Form 4 filing for Axsome Therapeutics, Inc. (AXSM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Feb 2026, 19:10.

Change

Previous filing in this sequence was filed on 02 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001219927 Primary reporting owner

TABUTEAU HERRIOT

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Signature: /s/ Herriot Tabuteau, M.D.
Signature date: 27 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXSM transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +54,623
Change %
Price: $0.000000
Shares after: 54,623
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 54,623
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant.